You are here

Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy

Last updated on August 5, 2019

FOR MORE INFORMATION
Study Location
Toronto General Hospital
Toronto, Ontario, M5G 2C4 Canada
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Transthyretin (TTR) Amyloid Cardiomyopathy
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

Cohort A: Completion of 30 months of study treatment on Pfizer Protocol B3461028

Cohort B: Patients in specific countries diagnosed with ATTR-CM who did not previously
participate in Pfizer Study B3461028

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

-Liver and/or heart transplant, or implanted cardiac mechanical assist device

NCT02791230
Pfizer
Recruiting
Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now